The New Guideline for Cervical Cancer Screening in Low Risk Iranian Women

Document Type : Original Article


1 Ph.D. Student of Cancer Management, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Professor, Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Specialist of Community Medicine, Cancer Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Assistant Professor, Department of Obstetrics and Gynecology, Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

6 Professor of Oncology Surgery, Cancer Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Introduction: The incidence rate of cervical cancer is lower in Iran compare to other countries; however, because of higher risk of cervical cancer deaths in this region, a cervical cancer screening program seems to be required. The aim of this study was to provide an organized approach to prevention and control of cervical cancer which could be feasible in other Muslim societies.
Methods: We conducted a systematic review of previous studies related to cervical cancer in Iran and reviewing the foreign country's guidelines. 190 articles about cervical cancer in Iran from 1971 to 2013 were studied. 13 articles were related to the data that we needed for developing the recommendation questions. We also reviewed the guidelines of World Health Organization and International Agency for Research on Cancer (IARC), GLOBOCON report, Iran Ministry of Health cancer registry report and 8 available foreign developed countries guidelines. Documents and papers with highest level and consistent with the aims of this review were selected and the Iran cervical cancer screening program was conducted by using the practical guideline development cycle. A questionnaire that included questions which have been answered in the guideline was designed. Expert panel make a decision for the necessity of cervical cancer screening program for Iran.
Results: We recommended an organized screening program with cytologic evaluation (Pap smear) that would be start at age 30, continued for every 5 years. The age for ending the screening is 69 years. There is no need to do screening for pregnant women and women who had hysterectomy.
Conclusion: Organized cervical cancer screening is a necessity for Iran, because we could not ignore more than 500-900 new cases with invasive cervical cancer that have been diagnosed every year in Iran.


  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 Dec 15;127(12):2893-917.
  2. Ferlay J ,Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013 Apr;49(6):1374-403.
  3. Globocan 2012: estimated cancer incidence and mortality and prevalenc worldwide in 2012. Available from:
  4. Health IMo. Iran Cancer Report 2009. Tehran:Cancer Registration Office;2012.
  5. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006 Aug 31;24 Suppl 3:S3/52-61.
  6. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012 Nov 20;30 Suppl 5:F12-23.
  7. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006 Jun;61(6 Suppl 1):S3-14.
  8. Aminisani N, Armstrong BK, Canfell K. Cervical cancer screening in Middle Eastern and Asian migrants to Australia: a record linkage study. Cancer Epidemiol 2012 Dec;36(6):e394-400.
  9. Bell RJ, Fradkin P, Parathithasan N, Robinson PJ, Schwarz M, Davis SR. Pregnancy-associated breast cancer and pregnancy following treatment for breast cancer, in a cohort of women from Victoria, Australia, with a first diagnosis of invasive breast cancer. Breast 2013 Oct;22(5):980-5.
  10. Barekat AA, Saidi F, Dutz W. Cancer survey in south Iran with special reference to gastrointestinal neoplasms. Int J Cancer 1971 Mar 15;7(2):353-63.
  11. Behmard S, Taherzadeh D, Gondos B. Cytologic screening for cervical cancer in southern Iran. Acta Cytol 1977 May-Jun;21(3):432-4.
  12. Habibi A. Cancer in Iran. A survey of the most common cases. J Natl Cancer Inst 1965 May;34:553-69.
  13. Habibi A. Cancer in Iran. Statistical review on 28,000 cases. Pathol Microbiol (Basel) 1970;35(1):181-3.
  14. Allahverdipour H, Emami A. Perceptions of cervical cancer threat, benefits, and barriers of Papanicolaou smear screening programs for women in Iran. Women Health 2008;47(3):23-37.
  15. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011 Dec;22(12):2675-86.
  16. Esmaeili M, Bonyadi M, Dastranj A, Alizadeh M, Melli MS, Shobeiri MJ. HPV typing in women with cervical precancerous and cancerous lesions in northwestern Iran. Gynecol Obstet Invest 2008;66(1):68-72.
  17. Khodakarami N, Clifford GM, Yavari P, Farzaneh F, Salehpour S, Broutet N, et al. Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer 2012 Jul 15;131(2:)E156-61.
  18. Haghshenas M, Golini-Moghaddam T, Rafiei A, Emadeian O, Shykhpour A, Ashrafi GH. Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study. Infect Agent Cancer 2013 Jun 6;8(1):20.
  19. Mortazavi S, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev 2002;3(1):69-72.
  20. Jaberipour M, Samsami A, Sahraiian F, Kazerooni T, Hashemi M, Ghaderi A, et al. Elevation of HPV-18 and HPV-16 DNA in the plasma of patients with advanced cervical cancer. Asian Pac J Cancer Prev 2011;12(1):163- 7.
  21. Seifi S, Asvadi Kermani I, Dolatkhah R, Asvadi Kermani A, Sakhinia E, Asgarzadeh M, et al. Prevalence of oral human papilloma virus in healthy individuals in East Azerbaijan province of Iran. Iran J Public Health 2013;42(1):79-85.
  22. Karimi Zarchi M, Akhavan A, Gholami H, Dehghani A, Naghshi M, Mohseni F. Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009. Asian Pac J Cancer Prev 2010;11(2):537-8.
  23. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, Rashidi B, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecol Oncol 2013 Feb;128(2):277-81.
  24. Nokiani FA, Akbari H, Rezaei M, Madani H, Ale Agha ME. Cost--effectiveness of pap smear in Kermanshah, Iran. Asian Pac J Cancer Prev 2008 Jan-Mar;9(1):107-10.
  25. de Bekker-Grob EW, de Kok IM, Bulten J, van Rosmalen J, Vedder JE, Arbyn M, et al. Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis. Cancer Causes Control 2012 Aug;23(8):1323-31.
  26. Duggan MA. Commentary on "Cervical cancer screening in England: the past, present, and future": a comparison with Canada. Cancer Cytopathol 2012 Apr 25;120(2):97-101.
  27. Rashid RM, Dahlui M, Mohamed M, Gertig D. Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries. Asian Pac J Cancer Prev 2013;14(3):2141-6.
  28. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012 May;119(6):699-709.
  29. Canadian Task Force on Preventive Health Care, Dickinson J, Tsakonas E, Conner Gorber S, Lewin G, Shaw E. Recommendations on screening for cervical cancer. CMAJ 2013 Jan 8;185(1):35-45.
  30. Castellsague X, Remy V, Puig-Tintore LM, de la Cuesta RS, Gonzalez-Rojas N, Cohet C. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain .J Low Genit Tract Dis 2009 Jan;13(1):38-45.
  31. Merea E, Le Gales C, Cochand-Priollet B, Cartier I, de Cremoux P, Vacher-Lavenu MC, et al. Cost of screening for cancerous and precancerous lesions of the cervix. Diagn Cytopathol 2002 Oct;27(4):251-7.
  32. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, et al. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors] [Article in Italian]. Epidemiol Prev 2012 May-Aug;36(3-4 Suppl 1):e1-72.
  33. Knight B. Cancer screening of the uterine cervix papanicolaou smears versus state-of-the-art human papillomavirus testing. Cancer Cytopathol 2012 Apr 25;120(2):105-7.
  34. Afrakhteh M, Khodakarami N, Moradi A, Alavi E, Hosseini Shirazi F. A Study of 13315 Papanicolau Smear Diagnoses in Shohada Hospital. J Fam Reprod Health 2007 Autumn1(2):75-9.
  35. Hoque M, Hoque E, Kader SB. Evaluation of cervical cancer screening program at a rural community of South Africa. East Afr J Public Health 2008 Aug;5(2):111-6.
  36. Kawonga M, Fonn S. Achieving effective cervical screening coverage in South Africa through human resources and health systems development. Reprod Health Matters 2008 Nov;16(32):32-40.
  37. WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva:World Health Organization;2013.
  38. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Geni Tract Dis 2013 Apr;17(2):193-202.
  39. Jin AZ, Louange EC, Chow KY, Fock CW. Evaluation of the National Cervical Cancer Screening Programme in Singapore. Singapore Med J 2013 Feb;54(2):96-101.
  40. Rustagi AS, Kamineni A, Weiss NS. Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women. Am J Epidemiol 2013 Oct 1;178(7):1020-2.
  41. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013 Mar-Apr;63(2):88-105.
  42. Karjane N, Chelmow D. New cervical cancer screening guidelines, again. Obstet Gynecol Clin North Am 2013 Jun;40(2):211-23.
  43. Simonella L, Canfell K. The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. Cancer Causes Control 2013 Sep;24(9):1727-36.
  44. Giorgi Rossi P, Ronco G. The present and future of cervical cancer screening programmes in Europe. Curr Pharm Des 2013;19(8):1490-7.
  45. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012 MayJun;62(3):147-72
  46. Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 2012 Aug;21(8):1354-61.
  47. David Luesley SL. Colposcopy and programme management. In: Programme NCS, editor. 2 ed. Fulwood House Old Fulwood Road Sheffield UK: NHS Cancer Screening Programmes 2010. p. 82.